Business Context and Reporting Period
This Form 8-K reports on the results of the 2013 Annual Meeting of Stockholders held by Harvard Bioscience, Inc. on May 23, 2013. The filing details the voting outcomes for four specific proposals submitted to security holders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results rather than financial performance.
Material Changes and Voting Results
Stockholders voted on the following proposals with the results summarized below:
- Proposal 1: Election of Directors
- Robert Dishman: Elected (14,969,401 For; 3,989,145 Withheld).
- Neal J. Harte: Elected (16,263,804 For; 2,694,742 Withheld).
- Both directors were elected to three-year terms ending in 2016.
- Proposal 2: Ratification of Auditors
- KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2013.
- Votes: 24,757,166 For; 66,932 Against; 6,438 Abstained.
- Proposal 3: Amendment to Employee Stock Purchase Plan
- Approved an increase of 250,000 authorized shares of common stock.
- Votes: 18,744,989 For; 178,143 Against; 35,414 Abstained.
- Proposal 4: Executive Compensation Advisory Vote
- Approved the compensation of named executive officers via a non-binding advisory vote.
- Votes: 13,939,719 For; 4,969,160 Against; 49,667 Abstained.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the reporting of the annual meeting outcomes.
Important Facts for Investors to Verify
- Confirmation that Robert Dishman and Neal J. Harte have assumed their roles as Class I Directors.
- Verification that KPMG LLP has formally commenced its audit responsibilities for the fiscal year ending December 31, 2013.
- Confirmation that the Employee Stock Purchase Plan has been legally amended to reflect the additional 250,000 authorized shares.
- Review of the specific executive compensation packages approved in the advisory vote to assess alignment with shareholder interests.